Chatham Capital Group Inc. Has $6.49 Million Stake in AbbVie Inc. $ABBV

Chatham Capital Group Inc. trimmed its holdings in AbbVie Inc. (NYSE:ABBV) by 8.0% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 28,011 shares of the company’s stock after selling 2,440 shares during the quarter. AbbVie comprises 0.9% of Chatham Capital Group Inc.’s portfolio, making the stock its 27th biggest holding. Chatham Capital Group Inc.’s holdings in AbbVie were worth $6,486,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of ABBV. Marshall & Sullivan Inc. WA bought a new stake in shares of AbbVie during the second quarter worth $25,000. Evolution Wealth Management Inc. acquired a new stake in shares of AbbVie in the 2nd quarter valued at approximately $26,000. TD Capital Management LLC boosted its position in shares of AbbVie by 82.9% during the first quarter. TD Capital Management LLC now owns 128 shares of the company’s stock worth $27,000 after purchasing an additional 58 shares in the last quarter. Spurstone Advisory Services LLC bought a new position in AbbVie during the second quarter worth about $28,000. Finally, Financial Gravity Companies Inc. acquired a new position in shares of AbbVie in the 2nd quarter valued at approximately $36,000. Institutional investors own 70.23% of the company’s stock.

AbbVie Price Performance

AbbVie stock opened at $230.18 on Thursday. The stock has a market capitalization of $406.81 billion, a P/E ratio of 174.38, a price-to-earnings-growth ratio of 1.30 and a beta of 0.36. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.60 and a current ratio of 0.72. AbbVie Inc. has a 52 week low of $164.39 and a 52 week high of $244.81. The stock has a fifty day moving average of $226.65 and a 200-day moving average of $212.00.

AbbVie (NYSE:ABBV) last posted its earnings results on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, topping analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The firm had revenue of $15.78 billion for the quarter, compared to analysts’ expectations of $15.58 billion. During the same quarter in the previous year, the firm posted $3.00 earnings per share. The company’s revenue was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. On average, sell-side analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be issued a $1.73 dividend. This is a boost from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date is Friday, January 16th. This represents a $6.92 dividend on an annualized basis and a yield of 3.0%. AbbVie’s dividend payout ratio (DPR) is 496.97%.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the stock. Citigroup reduced their target price on shares of AbbVie from $240.00 to $235.00 and set a “neutral” rating for the company in a research note on Monday, November 3rd. HSBC upgraded shares of AbbVie from a “hold” rating to a “buy” rating and boosted their target price for the stock from $225.00 to $265.00 in a report on Wednesday, December 10th. Evercore ISI boosted their price target on AbbVie from $207.00 to $222.00 and gave the stock an “outperform” rating in a research report on Monday, September 22nd. JPMorgan Chase & Co. increased their price objective on shares of AbbVie from $250.00 to $260.00 and gave the company an “overweight” rating in a research report on Monday, November 3rd. Finally, Wall Street Zen upgraded AbbVie from a “buy” rating to a “strong-buy” rating in a research note on Saturday, December 13th. Three analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and eight have assigned a Hold rating to the company. According to MarketBeat, AbbVie presently has a consensus rating of “Moderate Buy” and an average price target of $245.84.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.